Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 22, Issue 5, Pages 257-260
Focused Review

A new Era of Personalized Medicine for Cystic Fibrosis – at Last!

Bradley S Quon1,2 and Pearce G Wilcox1,2

1Centre for Heart Lung Innovation, University of British Columbia and St Paul’s Hospital, Canada
2Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Copyright © 2015 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The gene responsible for cystic fibrosis (CF) was discovered 25 years ago. This breakthrough has enabled a sophisticated understanding of how various mutations lead to specific alterations in the structure and function of the CF transmembrane regulator (CFTR) protein. Until recently, all therapies in CF were focused on ameliorating the downstream consequences of CFTR dysfunction. High-throughput drug screening approaches have yielded compounds that can modify CFTR structure and function, thus targeting the basic defect in CF. The present article describes the CFTR mutational classes, reviews mutation-specific therapies currently in late-phase clinical development, and highlights research opportunities and challenges with personalized medicine in CF.